| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S0031182009000493 |
| P698 | PubMed publication ID | 19281637 |
| P50 | author | Michael J. Doenhoff | Q41456714 |
| Paul Hagan | Q54802174 | ||
| P2093 | author name string | L A Tchuem Tchuenté | |
| D Engels | |||
| D Cioli | |||
| A Mbaye | |||
| G Coles | |||
| L Pica-Mattoccia | |||
| S Botros | |||
| V Southgate | |||
| P2860 | cites work | Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment | Q21090121 |
| Artemisinins and synthetic trioxolanes in the treatment of helminth infections | Q22061831 | ||
| Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases | Q28273898 | ||
| Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor | Q28469107 | ||
| Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target | Q28469234 | ||
| Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade | Q28472122 | ||
| Mefloquine--an aminoalcohol with promising antischistosomal properties in mice | Q28474353 | ||
| Projected benefits from integrating NTD programs in sub-Saharan Africa | Q29398511 | ||
| Control of neglected tropical diseases | Q29547285 | ||
| Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis | Q29619819 | ||
| Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa | Q29620602 | ||
| Rapid mapping of schistosomiasis and other neglected tropical diseases in the context of integrated control programmes in Africa. | Q30397196 | ||
| Towards control of schistosomiasis in sub-Saharan Africa. | Q30862703 | ||
| Schistosomiasis in African infants and preschool children: to treat or not to treat? | Q33269983 | ||
| The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase | Q34002522 | ||
| Schistosoma mansoni: chemotherapy of infections of different ages | Q34165519 | ||
| Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam | Q34200370 | ||
| Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal | Q34537724 | ||
| New policies for using anthelmintics in high risk groups | Q34959693 | ||
| Praziquantel | Q35156550 | ||
| Drugs for the control of parasitic diseases: current status and development in schistosomiasis | Q35569078 | ||
| Schistosomiasis control: keep taking the tablets. | Q35640594 | ||
| In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species | Q35758795 | ||
| Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action | Q36424568 | ||
| Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance | Q36441487 | ||
| A blueprint for success: integration of neglected tropical disease control programmes | Q36483770 | ||
| Schistosomiasis in the Senegal River Basin: before and after the construction of the dams at Diama, Senegal and Manantali, Mali and future prospects | Q36866804 | ||
| The unacknowledged impact of chronic schistosomiasis | Q37102843 | ||
| Clinical therapy of schistosomiasis mansoni: the Brazilian contribution | Q37212516 | ||
| Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis | Q37315241 | ||
| Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni. | Q38334612 | ||
| Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda | Q38881798 | ||
| Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt | Q38893135 | ||
| Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt | Q38916056 | ||
| Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice | Q38975063 | ||
| Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. | Q39034640 | ||
| Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. | Q39096387 | ||
| Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model. | Q39126736 | ||
| An international initiative on praziquantel use. | Q39392929 | ||
| The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal | Q39515105 | ||
| Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel | Q39544940 | ||
| Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection | Q39544948 | ||
| Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial | Q39544958 | ||
| Antischistosomal drugs: past, present ... and future? | Q40971899 | ||
| Genotoxic activity of praziquantel | Q41687493 | ||
| The global epidemiological situation of schistosomiasis and new approaches to control and research | Q42007538 | ||
| Parasitological evaluation of curative and subcurative doses of 9-acridanone-hydrazone drugs against Schistosoma mansoni in baboons, and observations on changes in serum levels of anti-egg antibodies detected by ELISA. | Q42208293 | ||
| The WHO dose pole for the administration of praziquantel is also accurate in non-African populations | Q42278366 | ||
| Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel | Q43655438 | ||
| Counterfeit praziquantel. | Q43729546 | ||
| Praziquantel--quality, dosages and markers of resistance | Q43784181 | ||
| Biological characteristics of praziquantel-resistant and -susceptible isolates of Schistosoma mansoni | Q43849942 | ||
| A safe, effective, herbal antischistosomal therapy derived from myrrh. | Q43855075 | ||
| Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel | Q44567644 | ||
| Creation by mutagenesis of a mammalian Ca(2+) channel beta subunit that confers praziquantel sensitivity to a mammalian Ca(2+) channel | Q44607347 | ||
| New initiatives against Africa's worms | Q44641296 | ||
| Specific sites in the Beta Interaction Domain of a schistosome Ca2+ channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel | Q44667713 | ||
| Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment | Q44795124 | ||
| Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates | Q44951797 | ||
| Lack of evidence for an antischistosomal activity of myrrh in experimental animals. | Q45015264 | ||
| Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1. | Q45754089 | ||
| Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni. | Q46019928 | ||
| The effect of single dose versus two doses of praziquantel on Schistosoma haematobium infection and pathology among school-aged children in Mali | Q46090821 | ||
| Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa | Q46214180 | ||
| Praziquantel resistance | Q46353137 | ||
| Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice | Q46400668 | ||
| Will new antischistosomal drugs finally emerge? | Q46449153 | ||
| Efficacy and Side Effects of Praziquantel in an Epidemic Focus of Schistosoma mansoni | Q46516480 | ||
| Schistosoma haematobium (Egyptian strain): rate of development and effect of praziquantel treatment. | Q46531457 | ||
| Praziquantel binds Schistosoma mansoni adult worm actin. | Q46531951 | ||
| Effect of praziquantel on the immature stages of Schistosoma haematobium. | Q46588110 | ||
| Schistosoma mansoni: lack of correlation between praziquantel-induced intra-worm calcium influx and parasite death | Q46612229 | ||
| Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. | Q46795013 | ||
| The influence of sampling effort and the performance of the Kato-Katz technique in diagnosing Schistosoma mansoni and hookworm co-infections in rural Côte d'Ivoire | Q46910554 | ||
| Leave children untreated and sustain inequity! | Q46930698 | ||
| Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates. | Q50956112 | ||
| Tolerance of Kenyan Schistosoma mansoni to oxamniquine. | Q53883370 | ||
| Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. | Q54199827 | ||
| Is Schistosomicidal Chemotherapy Sub-curative? Implications for Drug Resistance | Q56835755 | ||
| Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica | Q68025820 | ||
| Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro | Q68979501 | ||
| Alteration of Schistosoma mansoni malate dehydrogenase isoenzymes on passage in the laboratory | Q70647550 | ||
| Susceptibility to chemotherapeutic agents of strains of Schistosoma mansoni isolated from treated and untreated patients | Q71387379 | ||
| Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal | Q73408628 | ||
| Randomly amplified polymorphic DNA (RAPD) polymerase chain reaction assay for identification of Schistosoma mansoni strains sensitive or tolerant to anti-schistosomal drugs | Q73508242 | ||
| Efficacy of praziquantel against Schistosoma mansoni in northern Senegal | Q74841657 | ||
| Cytochalasin D abolishes the schistosomicidal activity of praziquantel | Q79328552 | ||
| Is actin the praziquantel receptor? | Q80584028 | ||
| A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets | Q80692175 | ||
| Praziquantel and the benzodiazepine Ro 11-3128 do not compete for the same binding sites in schistosomes | Q80983687 | ||
| Evidence for host-induced selection in Schistosoma mansoni | Q93577437 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Sub-Saharan Africa | Q132959 |
| schistosomiasis | Q221159 | ||
| praziquantel | Q424145 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1825-1835 | |
| P577 | publication date | 2009-03-13 | |
| P1433 | published in | Parasitology | Q15753259 |
| P1476 | title | Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs | |
| P478 | volume | 136 |
| Q36295193 | A multistrain approach to studying the mechanisms underlying compatibility in the interaction between Biomphalaria glabrata and Schistosoma mansoni. |
| Q28476171 | A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility |
| Q21562256 | A research agenda for helminth diseases of humans: Intervention for control and elimination |
| Q38123553 | Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis |
| Q47384586 | Analysis of the interactome of Schistosoma mansoni histone deacetylase 8. |
| Q45400770 | Anthelmintic effects of alkylated diamines and amino alcohols against Schistosoma mansoni |
| Q37846890 | Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control |
| Q28547348 | Application of RNAi to Genomic Drug Target Validation in Schistosomes |
| Q64933133 | Association between Schistosoma mansoni infection and access to improved water and sanitation facilities in Mwea, Kirinyaga County, Kenya. |
| Q83769924 | Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice |
| Q28539314 | Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis |
| Q24187049 | Circulating antigen tests and urine reagent strips for diagnosis of active schistosomiasis in endemic areas |
| Q34001292 | Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children |
| Q98729613 | Clusters of polymorphic transmembrane genes control resistance to schistosomes in snail vectors |
| Q46964347 | Control of schistosomiasis in sub-Saharan Africa: progress made, new opportunities and remaining challenges. |
| Q51551327 | Decades down the line: the viability of praziquantel for future schistosomiasis treatment. |
| Q28474926 | Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect schistosoma viability |
| Q34500892 | Differential anti-glycan antibody responses in Schistosoma mansoni-infected children and adults studied by shotgun glycan microarray |
| Q38118386 | Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race |
| Q36572029 | Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children |
| Q47956006 | Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum |
| Q59292299 | Effectiveness of the new integrated strategy to control the transmission of Schistosoma japonicum in China: a systematic review and meta-analysis |
| Q34496255 | Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt |
| Q54205301 | Efficacy of artemisinin-naphthoquine phosphate against Schistosoma haematobium adult flukes: dose-effect relationship and tegumental alterations. |
| Q21198915 | Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis |
| Q38867800 | Efficacy of praziquantel syrup versus crushed praziquantel tablets in the treatment of intestinal schistosomiasis in Ugandan preschool children, with observation on compliance and safety |
| Q28606875 | Exploring molecular variation in Schistosoma japonicum in China |
| Q36225955 | Flavonoids and Sesquiterpene Lactones from Artemisia absinthium and Tanacetum parthenium against Schistosoma mansoni Worms |
| Q34635112 | From a weighing scale to a pole: a comparison of two different dosage strategies in mass treatment of Schistosomiasis haematobium |
| Q28539660 | Functional characterization of a novel family of acetylcholine-gated chloride channels in Schistosoma mansoni |
| Q47988412 | Further studies on mefloquine and praziquantel alone or interaction of both drugs against Schistosoma japonicum in vitro |
| Q35776000 | Genome-Wide Scan and Test of Candidate Genes in the Snail Biomphalaria glabrata Reveal New Locus Influencing Resistance to Schistosoma mansoni |
| Q28551698 | High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni |
| Q93172815 | High-quality Schistosoma haematobium genome achieved by single-molecule and long-range sequencing |
| Q30372766 | Hyperdiverse gene cluster in snail host conveys resistance to human schistosome parasites |
| Q38974533 | Impact of gold nanoparticles on brain of mice infected with Schistosoma mansoni |
| Q26825064 | Impact of human schistosomiasis in sub-Saharan Africa |
| Q38648427 | In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium |
| Q37644571 | In vitro and in vivo trematode models for chemotherapeutic studies |
| Q34341901 | In vitro praziquantel test capable of detecting reduced in vivo efficacy in Schistosoma mansoni human infections |
| Q36851347 | Inferences on the biochemical and environmental regulation of universal stress proteins from Schistosomiasis parasites |
| Q36103626 | Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing). |
| Q24605622 | Isothermal microcalorimetry to study drugs against Schistosoma mansoni |
| Q28071848 | Mechanically produced schistosomula as a higher-throughput tools for phenotypic pre-screening in drug sensitivity assays: current research and future trends |
| Q55456465 | Methyl-CpG-binding (SmMBD2/3) and chromobox (SmCBX) proteins are required for neoblast proliferation and oviposition in the parasitic blood fluke Schistosoma mansoni. |
| Q35847008 | Modeling and Validation of Environmental Suitability for Schistosomiasis Transmission Using Remote Sensing |
| Q28536093 | Molecular cloning and characterization of novel glutamate-gated chloride channel subunits from Schistosoma mansoni |
| Q36834713 | Morphological Characteristics of Schistosoma mansoni PZQ-Resistant and -Susceptible Strains Are Different in Presence of Praziquantel |
| Q30378695 | Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies. |
| Q36656087 | Natural products as a source for treating neglected parasitic diseases |
| Q37177725 | New approaches for understanding mechanisms of drug resistance in schistosomes |
| Q37943763 | New insight into praziquantel against various developmental stages of schistosomes |
| Q35813630 | New insights into the genetic diversity of Schistosoma mansoni and S. haematobiumin Yemen |
| Q27008897 | Novel therapeutic and prevention approaches for schistosomiasis: review |
| Q86174393 | Parasitology: Rejuvenation through stem cells |
| Q41926627 | Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda |
| Q28484474 | Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children |
| Q35159499 | Pharmacology and potential physiological significance of schistosome multidrug resistance transporters |
| Q24635389 | Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic |
| Q39017026 | Present and future schistosomiasis control activities with support from the Schistosomiasis Control Initiative in West Africa |
| Q55342111 | Prevalence and intensity of Schistosoma haematobium infection among schoolchildren in central Zambia before and after mass treatment with a single dose of praziquantel. |
| Q34811057 | Proteomic profile of Bithynia siamensis goniomphalos snails upon infection with the carcinogenic liver fluke Opisthorchis viverrini. |
| Q27306710 | RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening |
| Q39034549 | Recent advances in proteomic applications for schistosomiasis research: potential clinical impact |
| Q34626126 | Repeated Schistosoma japonicum infection following treatment in two cohorts: evidence for host susceptibility to helminthiasis? |
| Q34125799 | Research and development of antischistosomal drugs in the People's Republic of China a 60-year review |
| Q35570876 | Schistosoma comparative genomics: integrating genome structure, parasite biology and anthelmintic discovery |
| Q41563730 | Schistosome infection aggravates HCV-related liver disease and induces changes in the regulatory T-cell phenotype. |
| Q91816690 | Schistosomiasis |
| Q39288169 | Schistosomiasis Sustained Control Program in Ethnic Groups Around Ninefescha (Eastern Senegal). |
| Q39031600 | Schistosomiasis elimination: lessons from the past guide the future |
| Q42559175 | Schistosomiasis in Africa: an emerging tragedy in our new global health decade |
| Q37427116 | Schistosomiasis in African infants and preschool children: let them now be treated! |
| Q24598949 | Schistosomiasis vaccines |
| Q35230008 | Screening trematodes for novel intervention targets: a proteomic and immunological comparison of Schistosoma haematobium, Schistosoma bovis and Echinostoma caproni. |
| Q37418403 | Significant variance in genetic diversity among populations of Schistosoma haematobium detected using microsatellite DNA loci from a genome-wide database |
| Q34071134 | Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine |
| Q46526867 | Structural changes of Schistosoma mansoni adult worms recovered from C57BL/6 mice treated with radiation-attenuated vaccine and/or praziquantel against infection |
| Q39373485 | Studies on the establishment of a co-culture system of lung stage Schistosoma japonicum with host cells. |
| Q39103077 | Targeting proteasomes in infectious organisms to combat disease |
| Q43924119 | The Efficacy of Single-Dose versus Double-Dose Praziquantel Treatments on Schistosoma mansoni Infections: Its Implication on Undernutrition and Anaemia among Primary Schoolchildren in Two On-Shore Communities, Northwestern Tanzania |
| Q34285344 | The N terminus of a schistosome beta subunit regulates inactivation and current density of a Cav2 channel |
| Q38870767 | The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda |
| Q46247381 | The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand |
| Q30061753 | The cross-cutting contribution of the end of neglected tropical diseases to the sustainable development goals |
| Q43256185 | The in vitro effect of mefloquine and praziquantel against juvenile and adult Schistosoma japonicum |
| Q94584886 | Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen |
| Q30239015 | Towards interruption of schistosomiasis transmission in sub-Saharan Africa: developing an appropriate environmental surveillance framework to guide and to support 'end game' interventions |
| Q28533891 | Transcriptome analyses of inhibitor-treated schistosome females provide evidence for cooperating Src-kinase and TGFβ receptor pathways controlling mitosis and eggshell formation |
| Q41414576 | Transmission electron microscopic observations on ultrastructural alterations in Schistosoma mansoni adult worms recovered from C57BL/6 mice treated with radiation-attenuated vaccine and/or praziquantel in addition to passive immunization with norma |
| Q40079529 | Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens |
| Q47985342 | Ultrastructural alterations of juvenile Schistosoma japonicum harbored in mice following mefloquine administration |
| Q33684408 | Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons |
| Q64232154 | WIPO Re:Search-A Platform for Product-Centered Cross-Sector Partnerships for the Elimination of Schistosomiasis |
| Q30049251 | Water, Sanitation, and Hygiene (WASH): A Critical Component for Sustainable Soil-Transmitted Helminth and Schistosomiasis Control |
| Q33716437 | Whole genome analysis of a schistosomiasis-transmitting freshwater snail. |
| Q28534863 | Whole-organ isolation approach as a basis for tissue-specific analyses in Schistosoma mansoni |
Search more.